# 🧬 Alpha-Agent: Self-Correction Report

## 1. Initial Design Review
- **Hotspot Target:** A_GLU_292 (Highest B-factor: 47.50)
- **Proposed Mutation:** HIS293Arg
- **Rationale:** Form a salt-bridge with GLU 292. Computed distance CA-CA is 3.78A, falling within the ideal salt-bridge range. Simulated visual inspection (Gemini 3.1 multimodal sandbox) indicated no immediate structural clashes.

## 2. In-vivo Experimental Feedback (Simulated)
- **Assay Type:** E. coli expression, heat shock at 60°C, followed by SDS-PAGE and DLS (Dynamic Light Scattering).
- **Result:** [FAILURE] The HIS293Arg variant showed massive aggregation in the inclusion bodies. DLS analysis revealed an increase in aggregate size compared to wild-type.
- **Multimodal Image Analysis (Simulated):** The SDS-PAGE showed weak soluble expression bands but heavy bands in the pellet fraction, strongly indicative of misfolding or surface hydrophobic exposure.

## 3. Agentic Failure Diagnosis
- **Hypothesis 1:** The introduction of ARG next to GLU may have formed the salt bridge, but ARG is exceedingly bulky. HIS293 was partially buried, and swapping it with a longer ARG side-chain displaced nearby solvent molecules, leading to the exposure of a cryptic hydrophobic patch (likely LEU 291).
- **Hypothesis 2:** The net charge alteration on the surface decreased global solubility at the expression temperature.

## 4. Self-Correction & Redesign
- **New Approach:** Instead of bulky ARG at 293, we will stabilize the region by targeting the adjacent generic loop. Let's mutate `SER290` to `ASP` or `GLU`, to pair with another naturally occurring nearby positive charge or simply introduce an anchor for solvent hydrogen-bonding to increase solubility.
- **Verification Requirement:** The new mutation must not increase hydrophobicity and must be surface-exposed.
- **[Evidence Card]**: 변이 SER290ASP는 친수성 표면적을 넓히고 부피를 줄여 Aggregation을 완화할 것으로 예측됨 (Logical Inference based on failure data).

## 5. Final Recommended Design
- **Variant Name:** PETase_Stable_v2 (SER290ASP)
- **Next Steps:** Proceed with synthesis and secondary in-vivo testing loop.
